CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Read MoreSafety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV₁ <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

TAKING CAYSTON®

Fast nebulization and flexible dosing

Nebulization typically takes 2-3 minutes,* 3 times daily, and at least 4 hours apart.

*This 2-3 minute estimate does not include setting up, cleaning, and disinfecting the ALTERA^® nebulizing equipment.

See below for how CAYSTON can fit into a patient's schedule

*This 2-3 minute estimate does not include setting up, cleaning, and disinfecting the ALTERA^® nebulizing equipment.

See below for how CAYSTON can fit into a patient's schedule

Play Demo

Try the Tool

Patients should place the nebulizer on a flat, stable surface and sit in an upright, comfortable position while administering CAYSTON.

Dosage and Administration of CAYSTON

CAYSTON should be administered 3 times a day for a 28-day course (followed by 28 days off CAYSTON therapy)
CAYSTON should only be administered using the ALTERA Nebulizer System and should not be administered with any other nebulizer
The ALTERA Nebulizer Handset should be cleaned after each use and disinfected before it’s used again¹¹
Patients should use a bronchodilator before each dose of CAYSTON
Patients taking several inhaled medications should be advised to use the medications in the following order of administration: bronchodilator, mucolytics, and lastly, CAYSTON
Patients should be advised to complete the full 28-day course of CAYSTON even if they are feeling better
CAYSTON does not need to be refrigerated in the 28 days after the pack has been opened

Get the CAYSTON Dosing and Administration Guide

"The flexibility of dosing allows us to plan our inhaled antibiotics around our busy and active lifestyle; as long as we take 3 doses a day, at least 4 hours apart, we are able to incorporate it into our routine."

Read about how real patients and caregivers like Kat and her son Quinn fit CAYSTON into their travel plans.

Remind patients to enroll at cayston.com/my-cayston-community

Storage of CAYSTON

Refrigeration/storage of CAYSTON: CAYSTON vial and diluent ampules should be stored in the refrigerator at 2 °C to 8 °C (36 °F to 46 °F) until needed. Once removed from the refrigerator, CAYSTON and diluent may be stored at room temperature (up to 25 °C/77 °F) for up to 28 days. Do not separate the CAYSTON vials from the diluent ampules. CAYSTON should be protected from light.

To take treatments away from home, refer your patients to sign up for a protective and convenient CAYSTON carrying case here.

Learn About Restarting CAYSTON

Tap for Important Safety Information

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

Continued below

Please read the following Important Safety Information before your video begins.

Important Safety Information and Indication

Contraindications

CAYSTON is contraindicated in patients with a known allergy to aztreonam.

INDICATION

CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV₁ <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.

Warnings and Precautions

Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.
Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV₁) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.
Decreases in FEV₁ After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV₁ during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV₁ declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV₁ measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV₁ are caused by a pulmonary exacerbation.
Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.

Indication

Please click here to see full Prescribing Information.

The information contained on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

ALLY, CAYSTON, the CAYSTON logo, CAYSTON ACCESS PROGRAM, the CAYSTON ACCESS PROGRAM logo, GILEAD, the GILEAD logo, and MY CAYSTON COMMUNITY are trademarks of Gilead Sciences, Inc. ALTERA is a registered trademark of PARI Pharma GmbH. All other trademarks referenced herein are the property of their respective owners.